

Arrhythmia

This page was last modified on 18 May 2016, at 10:06.

 Contents

- [Condition](#)
- [Guidance at RECRUITMENT for adult volunteer donor and maternal donor \(cord blood donation\)](#)
- [Guidance at CT /WORK-UP](#)
- [Individual at Risk](#)
- [Qualified Guidance](#)
 - [Acceptable](#)
 - [Unacceptable](#)
- [References](#)
- [Notes](#)

Condition

An abnormality of cardiac electrical activity, most commonly diagnosed by electrocardiography.

Guidance at RECRUITMENT for adult volunteer donor and maternal donor (cord blood donation)

QUALIFIED, SEE BELOW

Guidance at CT/WORK-UP

QUALIFIED, SEE BELOW

Individual at Risk

Donor

Qualified Guidance

Where possible, particularly at CT-stage and work-up, advice from a cardiologist should be sought.

Acceptable

Benign atrial or ventricular ectopics (extrasystoles)

Sinus tachycardia/bradycardia acceptable, but inform anaesthetist at work-up if for bone marrow harvest.

Beta-blockers prescribed for benign ectopics or sinus tachycardia are acceptable.

Supraventricular tachycardias (SVT), including atrial fibrillation/flutter, may be acceptable if successfully treated with catheter ablation and off rate /rhythm-control medications (such as beta-blockers) for at least one year.

Right bundle branch block in the absence of any other abnormality

First degree heart may be acceptable at work-up at the discretion of the assessing physician.

Unacceptable

Uncorrected atrial fibrillation/flutter

Any history of ventricular tachycardia/fibrillation

Wolff-Parkinson-White/Lown-Ganong-Levine syndromes unacceptable unless treated with catheter ablation, and no ECG evidence of accessory pathways.

Second (Mobitz type 1, 2 or Wenkebach) or third degree heart block

All pacemakers and implantable cardiac defibrillators (ICD)

Left bundle branch block

Long-QT syndrome, Brugada syndrome or any other known cause of sudden cardiac death

References

Halter J, Kadera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. *Haematologica* 2009; 94(1): 94-101.

Komatsu F, Shikata M. Abnormal electrocardiographic findings in apheresis donors. *Transfusion* 1988; 28(4): 371-4.

Laspina SJ, Browne MA, McSweeney EN, Lawlor J, Whelan DM, Kinsella AL et al. QTc prolongation in apheresis platelet donors. *Transfusion* 2002; 42(7): 899-903.

Povsic TJ, Losordo DW, Story K, Junge CE, Schatz RA, Harrington RA et al. Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. *Am Heart J* 2012; 164(5): 689-697 e3.

Yuan S, Ziman A, Smeltzer B, Lu Q, Goldfinger D. Moderate and severe adverse events associated with apheresis donations: incidences and risk factors. *Transfusion* 2010; 50(2): 478-86.

Notes

One member of the review committee the acceptability of donors with a history of supraventricular tachycardia treated with catheter ablation and off rate-control medication for one year.